

John P Bilezikian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3147245/publications.pdf>

Version: 2024-02-01

303
papers

37,106
citations

3334

91
h-index

3323

184
g-index

337
all docs

337
docs citations

337
times ranked

26010
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Post-acute COVID-19 syndrome. <i>Nature Medicine</i> , 2021, 27, 601-615. | 30.7 | 3,051 |
| 2 | Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032. | 30.7 | 2,300 |
| 3 | Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3561-3569. | 3.6 | 1,277 |
| 4 | The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2003, 349, 1207-1215. | 27.0 | 1,133 |
| 5 | Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2990-3011. | 3.6 | 1,127 |
| 6 | A 10-Year Prospective Study of Primary Hyperparathyroidism with or without Parathyroid Surgery. <i>New England Journal of Medicine</i> , 1999, 341, 1249-1255. | 27.0 | 822 |
| 7 | Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 335-339. | 3.6 | 793 |
| 8 | Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 518-530. | 2.8 | 617 |
| 9 | Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. <i>Endocrine Reviews</i> , 2019, 40, 1109-1151. | 20.1 | 611 |
| 10 | Increased Bone Mass as a Result of Estrogen Therapy in a Man with Aromatase Deficiency. <i>New England Journal of Medicine</i> , 1998, 339, 599-603. | 27.0 | 585 |
| 11 | Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1846-1853. | 2.8 | 580 |
| 12 | Summary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5353-5361. | 3.6 | 577 |
| 13 | Mechanisms of Anabolic Therapies for Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 357, 905-916. | 27.0 | 573 |
| 14 | One Year of Alendronate after One Year of Parathyroid Hormone (1 α -84) for Osteoporosis. <i>New England Journal of Medicine</i> , 2005, 353, 555-565. | 27.0 | 568 |
| 15 | Skeletal disease in primary hyperparathyroidism. <i>Journal of Bone and Mineral Research</i> , 1989, 4, 283-291. | 2.8 | 553 |
| 16 | The Natural History of Primary Hyperparathyroidism with or without Parathyroid Surgery after 15 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3462-3470. | 3.6 | 505 |
| 17 | Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2317-2337. | 2.8 | 485 |
| 18 | Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1802-1822. | 3.6 | 480 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 135-141. | 3.6 | 425 |
| 20 | Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 ISCD Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2008, 11, 75-91. | 1.2 | 379 |
| 21 | Hyperparathyroidism. <i>Lancet, The</i> , 2018, 391, 168-178. | 13.7 | 371 |
| 22 | Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 157-166. | 3.6 | 356 |
| 23 | Parathyroid hormone: anabolic and catabolic actions on the skeleton. <i>Current Opinion in Pharmacology</i> , 2015, 22, 41-50. | 3.5 | 355 |
| 24 | Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3114-3121. | 3.6 | 347 |
| 25 | Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3069-3076. | 3.6 | 331 |
| 26 | Asymptomatic Primary Hyperparathyroidism. <i>New England Journal of Medicine</i> , 2004, 350, 1746-1751. | 27.0 | 328 |
| 27 | The Histomorphometry of Bone in Primary Hyperparathyroidism: Preservation of Cancellous Bone Structure*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 930-938. | 3.6 | 318 |
| 28 | Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3580-3594. | 3.6 | 318 |
| 29 | Glucocorticoid-induced osteoporosis: an update. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 144-149. | 7.1 | 311 |
| 30 | Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. <i>Cell Metabolism</i> , 2017, 25, 661-672. | 16.2 | 308 |
| 31 | Management of Hypoparathyroidism: Summary Statement and Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2273-2283. | 3.6 | 303 |
| 32 | Management of Acute Hypercalcemia. <i>New England Journal of Medicine</i> , 1992, 326, 1196-1203. | 27.0 | 267 |
| 33 | The Influence of Hypermagnesemia on Serum Calcium and Parathyroid Hormone Levels in Human Subjects. <i>New England Journal of Medicine</i> , 1984, 310, 1221-1225. | 27.0 | 262 |
| 34 | Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3319-3325. | 3.6 | 262 |
| 35 | MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. <i>European Journal of Endocrinology</i> , 2020, 183, R133-R147. | 3.7 | 259 |
| 36 | Presentation of Hypoparathyroidism: Etiologies and Clinical Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2300-2312. | 3.6 | 246 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 275-283. | 11.4 | 244 |
| 38 | Parathyroid Carcinoma. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1869-1880. | 2.8 | 243 |
| 39 | The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5644-5649. | 3.6 | 235 |
| 40 | Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 447-456. | 8.0 | 233 |
| 41 | The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. <i>American Journal of Medicine</i> , 1999, 107, 561-567. | 1.5 | 231 |
| 42 | Epidemiology and Diagnosis of Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2284-2299. | 3.6 | 230 |
| 43 | Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1150-1156. | 3.6 | 228 |
| 44 | Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 44-51. | 3.6 | 212 |
| 45 | Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2194-2207. | 2.4 | 211 |
| 46 | Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3785-3793. | 3.6 | 205 |
| 47 | Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3993-4004. | 3.6 | 197 |
| 48 | Osteoporosis in Men*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3431-3434. | 3.6 | 189 |
| 49 | Anabolic Therapy for Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 957-964. | 3.6 | 187 |
| 50 | Incipient Primary Hyperparathyroidism: A Forme Fruste of an Old Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5348-5352. | 3.6 | 186 |
| 51 | Primary hyperparathyroidism. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16033. | 30.5 | 180 |
| 52 | Dynamic and Structural Properties of the Skeleton in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 2018-2024. | 2.8 | 176 |
| 53 | Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1029-1040. | 2.8 | 174 |
| 54 | The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4033-4041. | 3.6 | 173 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Morphometric Vertebral Fractures in Postmenopausal Women with Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2306-2312. | 3.6 | 170 |
| 56 | The Effect of PTH(1-84) on Quality of Life in Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2356-2361. | 3.6 | 169 |
| 57 | Insulin-Like Growth Factor-I in Men with Idiopathic Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2799-2805. | 3.6 | 167 |
| 58 | Aromatase Activity and Bone Homeostasis in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5898-5907. | 3.6 | 164 |
| 59 | The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. <i>Osteoporosis International</i> , 2004, 15, 992-997. | 3.1 | 161 |
| 60 | Treatment of Hypercalcemia Secondary to Parathyroid Carcinoma with a Novel Calcimimetic Agent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1083-1088. | 3.6 | 160 |
| 61 | High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 746-756. | 2.8 | 160 |
| 62 | Management of Hypoparathyroidism: Present and Future. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2313-2324. | 3.6 | 151 |
| 63 | Therapy of Hypoparathyroidism with PTH(1-84): A Prospective Four-Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 137-144. | 3.6 | 148 |
| 64 | Normocalcemic Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013, 16, 33-39. | 1.2 | 145 |
| 65 | Hypoparathyroidism. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17055. | 30.5 | 142 |
| 66 | Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis. <i>American Journal of Medicine</i> , 2009, 122, S14-S21. | 1.5 | 140 |
| 67 | Differing effects of denosumab and alendronate on cortical and trabecular bone. <i>Bone</i> , 2014, 59, 173-179. | 2.9 | 135 |
| 68 | Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2766-2772. | 3.6 | 134 |
| 69 | Arterial Stiffness in Mild Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3326-3330. | 3.6 | 132 |
| 70 | Pharmacology of bisphosphonates. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1052-1062. | 2.4 | 132 |
| 71 | ACTIVEExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2949-2957. | 3.6 | 131 |
| 72 | Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 913-920. | 2.8 | 130 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1393-1399. | 2.8 | 127 |
| 74 | Safety of osteoanabolic therapy: A decade of experience. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2419-2428. | 2.8 | 125 |
| 75 | Prevalence of Kidney Stones and Vertebral Fractures in Primary Hyperparathyroidism Using Imaging Technology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1309-1315. | 3.6 | 125 |
| 76 | PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2727-2736. | 2.8 | 122 |
| 77 | Utility of the trabecular bone score (TBS) in secondary osteoporosis. <i>Endocrine</i> , 2014, 47, 435-448. | 2.3 | 120 |
| 78 | Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. <i>American Journal of Medicine</i> , 1989, 87, 553-557. | 1.5 | 118 |
| 79 | Controversies in Vitamin D: A Statement From the Third International Conference. <i>JBMR Plus</i> , 2020, 4, e10417. | 2.7 | 118 |
| 80 | Primary Hyperparathyroidism. <i>F1000Research</i> , 2016, 5, 1. | 1.6 | 117 |
| 81 | Normocalcemic Hyperparathyroidism and Hypoparathyroidism in Two Community-Based Nonreferral Populations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2734-2741. | 3.6 | 116 |
| 82 | The use of parathyroid hormone in the treatment of osteoporosis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2006, 7, 113-121. | 5.7 | 114 |
| 83 | Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 200-210. | 3.0 | 109 |
| 84 | Bone disease in primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 553-561. | 1.3 | 104 |
| 85 | PTH(1-84) Is Associated With Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3694-3699. | 3.6 | 104 |
| 86 | Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window. <i>Current Osteoporosis Reports</i> , 2008, 6, 24-30. | 3.6 | 103 |
| 87 | Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1722-1736. | 3.6 | 103 |
| 88 | Parathyroid hormone and the cardiovascular system. <i>Current Osteoporosis Reports</i> , 2008, 6, 77-83. | 3.6 | 102 |
| 89 | Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2742-2750. | 3.6 | 101 |
| 90 | Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism. <i>Radiology</i> , 2019, 291, 469-476. | 7.3 | 101 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Clinical Utility of an Immunoradiometric Assay for Parathyroid Hormone (1 α -84) in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4725-4730. | 3.6 | 94 |
| 92 | The anabolic effects of parathyroid hormone therapy. <i>Clinics in Geriatric Medicine</i> , 2003, 19, 415-432. | 2.6 | 93 |
| 93 | Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1519-1528. | 3.6 | 92 |
| 94 | Normocalcemic primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 106-109. | 1.3 | 88 |
| 95 | Hypocalcemic Emergencies. <i>Endocrinology and Metabolism Clinics of North America</i> , 1993, 22, 363-375. | 3.2 | 87 |
| 96 | Osteoporosis in Men. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 399-419. | 3.2 | 86 |
| 97 | Three dimensional cancellous bone structure in hypoparathyroidism. <i>Bone</i> , 2010, 46, 190-195. | 2.9 | 84 |
| 98 | The cell biology of parathyroid hormone in osteoblasts. <i>Current Osteoporosis Reports</i> , 2008, 6, 72-76. | 3.6 | 83 |
| 99 | The Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism Revisited. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 333-334. | 3.6 | 83 |
| 100 | Asymptomatic Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013, 16, 14-21. | 1.2 | 83 |
| 101 | An N-Terminal Molecular Form of Parathyroid Hormone (PTH) Distinct from hPTH(1 α -84) Is Overproduced in Parathyroid Carcinoma. <i>Clinical Chemistry</i> , 2007, 53, 1470-1476. | 3.2 | 81 |
| 102 | Primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 593-607. | 4.7 | 81 |
| 103 | Better skeletal microstructure confers greater mechanical advantages in Chinese-American women versus white women. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1783-1792. | 2.8 | 80 |
| 104 | Romosozumab for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 255-263. | 3.1 | 78 |
| 105 | New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. <i>Bone</i> , 2013, 55, 57-63. | 2.9 | 76 |
| 106 | The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. <i>Journal of Bone and Mineral Research</i> , 1986, 1, 383-388. | 2.8 | 75 |
| 107 | Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1201-1218. | 5.7 | 74 |
| 108 | Primary Hyperparathyroidism: Still Evolving?. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 856-862. | 2.8 | 73 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Trabecular Bone Score Is Associated With Volumetric Bone Density and Microarchitecture as Assessed by Central QCT and HRpQCT in Chinese American and White Women. <i>Journal of Clinical Densitometry</i> , 2013, 16, 554-561. | 1.2 | 73 |
| 110 | New Observations on Bone Quality in Mild Primary Hyperparathyroidism as Determined by Quantitative Backscattered Electron Imaging. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 717-723. | 2.8 | 71 |
| 111 | Differentiation and Proliferation of Periosteal Osteoblast Progenitors Are Differentially Regulated by Estrogens and Intermittent Parathyroid Hormone Administration. <i>Endocrinology</i> , 2008, 149, 5713-5723. | 2.8 | 71 |
| 112 | Osteitis fibrosa cystica—a forgotten radiological feature of primary hyperparathyroidism. <i>Endocrine</i> , 2017, 58, 380-385. | 2.3 | 70 |
| 113 | Anabolic Therapy for Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 957-964. | 3.6 | 70 |
| 114 | Parathyroid Hormone as an Anabolic Skeletal Therapy. <i>Drugs</i> , 2005, 65, 2481-2498. | 10.9 | 69 |
| 115 | Circulating Sclerostin in Disorders of Parathyroid Gland Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3804-3810. | 3.6 | 68 |
| 116 | Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 308-316. | 2.8 | 67 |
| 117 | Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. <i>European Journal of Endocrinology</i> , 2005, 152, 199-205. | 3.7 | 66 |
| 118 | Endothelial cells contain beta adrenoceptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1984, 325, 310-313. | 3.0 | 64 |
| 119 | Combination therapy with risedronate and teriparatide in male osteoporosis. <i>Endocrine</i> , 2013, 44, 237-246. | 2.3 | 63 |
| 120 | Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: A prospective analysis of the NHANES I follow-up study. <i>American Journal of Medicine</i> , 2004, 117, 169-174. | 1.5 | 62 |
| 121 | Sclerostin: Therapeutic Horizons Based Upon Its Actions. <i>Current Osteoporosis Reports</i> , 2012, 10, 64-72. | 3.6 | 62 |
| 122 | Marked Improvement in Bone Mass after Parathyroidectomy in Osteitis Fibrosa Cystica. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 732-735. | 3.6 | 60 |
| 123 | Clinical spectrum of primary hyperparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2000, 1, 237-245. | 5.7 | 60 |
| 124 | New anabolic therapies in osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2003, 32, 285-307. | 3.2 | 60 |
| 125 | Optimal Dietary Calcium Intake in Primary Hyperparathyroidism. <i>American Journal of Medicine</i> , 1997, 102, 543-550. | 1.5 | 59 |
| 126 | Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. <i>Bone</i> , 2011, 48, 557-561. | 2.9 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 722-731. | 3.6 | 59 |
| 128 | Normal Growth Hormone Secretary Reserve in Men with Idiopathic Osteoporosis and Reduced Circulating Levels of Insulin-Like Growth Factor-11. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2576-2579. | 3.6 | 58 |
| 129 | Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3535-3541. | 3.6 | 55 |
| 130 | Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. <i>European Journal of Endocrinology</i> , 2015, 172, 527-535. | 3.7 | 55 |
| 131 | Management of normocalcemic primary hyperparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 837-845. | 4.7 | 55 |
| 132 | Bone Densitometry: The Best Way to Detect Osteoporosis and to Monitor Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1867-1871. | 3.6 | 55 |
| 133 | Diagnosis and management of primary hyperparathyroidism: a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2013, 57, 406-424. | 1.3 | 54 |
| 134 | Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5601-5610. | 3.6 | 53 |
| 135 | Case Report Vitamin A Toxicity and Hypercalcemia. <i>American Journal of the Medical Sciences</i> , 1982, 283, 161-164. | 1.1 | 52 |
| 136 | Sex Steroids, Mice, and Men: When Androgens and Estrogens Get Very Close to Each Other. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 563-566. | 2.8 | 51 |
| 137 | Alendronate Therapy in Men With Primary Hyperparathyroidism. <i>Endocrine Practice</i> , 2009, 15, 705-713. | 2.1 | 51 |
| 138 | Trabecular bone score: perspectives of an imaging technology coming of age. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 493-503. | 1.3 | 51 |
| 139 | Positive Chronotropic Actions of Parathyroid Hormone and Parathyroid Hormone-Related Peptide Are Associated With Increases in the Current, I_f , and the Slope of the Pacemaker Potential. <i>Circulation</i> , 1997, 96, 3704-3709. | 1.6 | 48 |
| 140 | Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 220-226. | 1.3 | 47 |
| 141 | Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. <i>Endocrine</i> , 2017, 55, 273-282. | 2.3 | 47 |
| 142 | Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. <i>Endocrine</i> , 2017, 55, 591-598. | 2.3 | 47 |
| 143 | Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5136-5147. | 3.6 | 46 |
| 144 | Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. <i>Bone Research</i> , 2013, 1, 162-169. | 11.4 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 196-205. | 3.6 | 45 |
| 146 | Osteoanabolic and dual action drugs. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1084-1094. | 2.4 | 45 |
| 147 | Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2748-2756. | 3.6 | 44 |
| 148 | Stimulation of inositol phosphate formation in ros 17/2.8 cell membranes by guanine nucleotide, calcium, and parathyroid hormone. <i>Journal of Bone and Mineral Research</i> , 1989, 4, 413-420. | 2.8 | 43 |
| 149 | AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. <i>Head and Neck</i> , 2018, 40, 1617-1629. | 2.0 | 43 |
| 150 | Bone strength in primary hyperparathyroidism. <i>Osteoporosis International</i> , 2003, 14, 113-117. | 3.1 | 37 |
| 151 | More bone density testing is needed, not less. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 739-742. | 2.8 | 37 |
| 152 | Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2609-e2616. | 3.6 | 37 |
| 153 | Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. <i>Journal of Bone and Mineral Research</i> , 2002, 17 Suppl 2, N2-11. | 2.8 | 37 |
| 154 | Effect of Renal Function on Skeletal Health in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1501-1507. | 3.6 | 36 |
| 155 | Stress fractures: concepts and therapeutics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2720. | 3.6 | 36 |
| 156 | New Approaches to the Treatment of Osteoporosis. <i>Annual Review of Medicine</i> , 2011, 62, 307-322. | 12.2 | 35 |
| 157 | Primary Hyperparathyroidism. <i>Endocrine Practice</i> , 2012, 18, 781-790. | 2.1 | 35 |
| 158 | Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism – translating the pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 252-267. | 2.4 | 35 |
| 159 | Bone Turnover Markers in Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013, 16, 22-27. | 1.2 | 34 |
| 160 | Initiation of dapagliflozin and treatment – emergent fractures. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1070-1074. | 4.4 | 33 |
| 161 | The Official Positions of the International Society for Clinical Densitometry: Perceptions and Commentary. <i>Journal of Clinical Densitometry</i> , 2009, 12, 267-271. | 1.2 | 32 |
| 162 | Mini-review: new therapeutic options in hypoparathyroidism. <i>Endocrine</i> , 2012, 41, 410-414. | 2.3 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. <i>Endocrine</i> , 2017, 55, 3-5. | 2.3 | 32 |
| 164 | Signs and Symptoms of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 759-770. | 3.2 | 32 |
| 165 | Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 681-689. | 3.3 | 31 |
| 166 | Estrogens and Postmenopausal Osteoporosis: Was Albright Right After All?. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 774-776. | 2.8 | 30 |
| 167 | Asymptomatic primary hyperparathyroidism: a medical perspective. <i>Surgical Clinics of North America</i> , 2004, 84, 787-801. | 1.5 | 30 |
| 168 | Glucocorticoid-Induced osteoporosis: clinical and therapeutic aspects. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1404-1412. | 1.3 | 30 |
| 169 | Update on romosozumab: a humanized monoclonal antibody to sclerostin. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 697-707. | 3.1 | 30 |
| 170 | Parathyroid hormone therapy for hypoparathyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015, 29, 47-55. | 4.7 | 29 |
| 171 | Patient-specific bone modelling and remodelling simulation of hypoparathyroidism based on human iliac crest biopsies. <i>Journal of Biomechanics</i> , 2012, 45, 2411-2416. | 2.1 | 27 |
| 172 | PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 180-189. | 2.8 | 27 |
| 173 | Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1512-1521. | 3.6 | 27 |
| 174 | Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 789-802. | 5.7 | 27 |
| 175 | Tc99m-Sestamibi Uptake in Osteitis Fibrosa Cystica Simulating Metastatic Bone Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5138-5141. | 3.6 | 26 |
| 176 | Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 942-947. | 3.6 | 26 |
| 177 | Novel Therapies for Postmenopausal Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 207-219. | 3.2 | 25 |
| 178 | Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. <i>Current Medical Research and Opinion</i> , 2019, 35, 2097-2102. | 1.9 | 25 |
| 179 | Bone Mineral Density: Clinical Relevance and Quantitative Assessment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 446-454. | 5.0 | 25 |
| 180 | Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. <i>Endocrine</i> , 2021, 71, 267-269. | 2.3 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 297-316. | 5.7 | 25 |
| 182 | Circulating Sclerostin Levels and Markers of Bone Turnover in Chinese-American and White Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4736-4743. | 3.6 | 24 |
| 183 | Primary hyperparathyroidism: recent advances. <i>Current Opinion in Rheumatology</i> , 2018, 30, 427-439. | 4.3 | 24 |
| 184 | The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1931-1939. | 2.8 | 24 |
| 185 | Bone Quality determined by Fourier Transform Infrared Imaging Analysis in Mild Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3484-3489. | 3.6 | 23 |
| 186 | Bone markers and osteoporosis therapy. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 504-513. | 1.3 | 23 |
| 187 | New and developing pharmacotherapy for osteoporosis in men. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 253-264. | 1.8 | 23 |
| 188 | A radioreceptor assay for propranolol. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 173-180. | 4.7 | 22 |
| 189 | Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. <i>Current Osteoporosis Reports</i> , 2006, 4, 5-13. | 3.6 | 22 |
| 190 | Osteoporosis Update From the 2010 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2011, 14, 1-21. | 1.2 | 22 |
| 191 | Combination Anabolic and Antiresorptive Therapy for Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 643-654. | 3.2 | 22 |
| 192 | PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 5-13. | 2.4 | 22 |
| 193 | Rare Causes of Hypercalcemia: 2021 Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3113-3128. | 3.6 | 22 |
| 194 | Asymptomatic primary hyperparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2006, 50, 647-656. | 1.3 | 21 |
| 195 | Idiopathic Osteoporosis in Men. <i>Current Osteoporosis Reports</i> , 2013, 11, 286-298. | 3.6 | 21 |
| 196 | Vertebral Fracture Assessment in Postmenopausal Women With Postsurgical Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1303-1311. | 3.6 | 21 |
| 197 | Parathyroid hormone stimulates formation of inositol phosphates in a membrane preparation of canine renal cortical tubular cells. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 299-306. | 2.8 | 20 |
| 198 | Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1115-e1123. | 3.6 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | Recovery of Parathyroid Hormone Secretion and Function in Postoperative Hypoparathyroidism: A Case Series. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4285-4290. | 3.6 | 19 |
| 200 | Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 2132-2139. | 2.8 | 19 |
| 201 | Combination antiresorptive and osteoanabolic therapy for osteoporosis: We are not there yet. <i>Current Medical Research and Opinion</i> , 2011, 27, 1705-1707. | 1.9 | 18 |
| 202 | Therapy of Osteoporosis in Men with Teriparatide. <i>Journal of Osteoporosis</i> , 2011, 2011, 1-7. | 0.5 | 18 |
| 203 | Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1082-1088. | 2.8 | 18 |
| 204 | Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25- μ g or 50- μ g Daily Doses. <i>Clinical Therapeutics</i> , 2017, 39, 2096-2102. | 2.5 | 18 |
| 205 | Sclerostin measurement in human disease: Validity and current limitations. <i>Bone</i> , 2017, 96, 24-28. | 2.9 | 18 |
| 206 | Vitamin D supplementation and musculoskeletal health. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 85-86. | 11.4 | 18 |
| 207 | 2009 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2010, 13, 1-9. | 1.2 | 17 |
| 208 | Modifications of the adenylate cyclase complex during differentiation of cultured myoblasts. <i>Journal of Cellular Physiology</i> , 1986, 127, 28-38. | 4.1 | 16 |
| 209 | Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3557-e3565. | 3.6 | 16 |
| 210 | Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the future. <i>Journal of Bone and Mineral Research</i> , 2002, 17 Suppl 2, N57-67. | 2.8 | 15 |
| 211 | Osteoporosis Update From the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2013, 16, 584-600. | 1.2 | 14 |
| 212 | Beyond Dxa: Advances in Clinical Applications of New Bone Imaging Technology. <i>Endocrine Practice</i> , 2016, 22, 990-998. | 2.1 | 14 |
| 213 | Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1-84) Therapy in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1274-1281. | 2.8 | 14 |
| 214 | Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab. <i>Osteoporosis and Bone Diseases</i> , 2018, 21, 17-22. | 1.4 | 14 |
| 215 | A radioreceptor assay for propranolol and 4-hydroxypropranolol. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 32-39. | 4.7 | 13 |
| 216 | Asymptomatic Primary Hyperparathyroidism: a Commentary on the Revised Guidelines. <i>Endocrine Practice</i> , 2009, 15, 494-498. | 2.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 217 | Primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2024, 38, 101247. | 4.7 | 13 |
| 218 | Three generational phenotypes of sporadic primary hyperparathyroidism: evolution defined by technology. Lancet Diabetes and Endocrinology, the, 2019, 7, 745-747. | 11.4 | 13 |
| 219 | Hospital care for primary hyperparathyroidism in Italy: a 6-year register-based study. European Journal of Endocrinology, 2014, 171, 481-487. | 3.7 | 12 |
| 220 | Update on hypoparathyroidism. Current Opinion in Rheumatology, 2019, 31, 381-387. | 4.3 | 12 |
| 221 | Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Current Medical Research and Opinion, 2020, 36, 1861-1872. | 1.9 | 12 |
| 222 | Hypomagnesuria is Associated With Nephrolithiasis in Patients With Asymptomatic Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2789-e2795. | 3.6 | 12 |
| 223 | Infection of L6E9 myoblasts with Trypanosoma cruzi alters adenylate cyclase activity and guanine nucleotide binding proteins. Journal of Cellular Physiology, 1987, 133, 64-71. | 4.1 | 11 |
| 224 | Parathyroid Hormone in the Evaluation of Hypercalcemia. JAMA - Journal of the American Medical Association, 2014, 312, 2680. | 7.4 | 11 |
| 225 | Clinical phenotypes of primary hyperparathyroidism in hospitalized patients who underwent parathyroidectomy. Endocrine Connections, 2021, 10, 248-255. | 1.9 | 11 |
| 226 | DXA-Based Bone Strain Index: A New Tool to Evaluate Bone Quality in Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2304-2312. | 3.6 | 11 |
| 227 | Racial differences in bone density and fracture risk in the United States. International Journal of Rheumatic Diseases, 2008, 11, 341-346. | 1.9 | 10 |
| 228 | Stop the war on DXA!. Annals of the New York Academy of Sciences, 2018, 1433, 12-17. | 3.8 | 10 |
| 229 | New Directions in Treatment of Hypoparathyroidism. Endocrinology and Metabolism Clinics of North America, 2018, 47, 901-915. | 3.2 | 10 |
| 230 | Report on the Audit on Burden of Osteoporosis in Eight Countries of the Eurasian Region: Armenia, Belarus, Georgia, Moldova, Kazakhstan, the Kyrgyz Republic, the Russian Federation, and Uzbekistan. Archives of Osteoporosis, 2020, 15, 175. | 2.4 | 10 |
| 231 | The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 485-501. | 5.7 | 10 |
| 232 | Total and free propranolol levels in sensitive and resistant patients. Clinical Pharmacology and Therapeutics, 1983, 33, 163-171. | 4.7 | 9 |
| 233 | Hypoparathyroidism. Current Opinion in Endocrinology, Diabetes and Obesity, 1997, 4, 427-432. | 0.6 | 9 |
| 234 | Osteoporosis in men: Pathophysiology and treatment. Current Rheumatology Reports, 2007, 9, 71-77. | 4.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 235 | Anabolic Therapy for Osteoporosis. <i>Women's Health</i> , 2007, 3, 243-253. | 1.5 | 8 |
| 236 | New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. <i>Bone Research</i> , 2014, 2, 14043. | 11.4 | 8 |
| 237 | How Long to Treat with Denosumab. <i>Current Osteoporosis Reports</i> , 2015, 13, 415-420. | 3.6 | 8 |
| 238 | Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial. <i>Archives of Endocrinology and Metabolism</i> , 2016, 60, 54-59. | 0.6 | 8 |
| 239 | In vivo precision of digital topological skeletonization based individual trabecula segmentation (ITS) analysis of trabecular microstructure at the distal radius and tibia by HR-pQCT. <i>Pattern Recognition Letters</i> , 2016, 76, 83-89. | 4.2 | 8 |
| 240 | Trabecular bone score: a useful clinical tool for the evaluation of skeletal health in women of short stature. <i>Endocrine</i> , 2019, 66, 398-404. | 2.3 | 8 |
| 241 | Clinical Presentation of Hypoparathyroidism. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab003. | 0.2 | 8 |
| 242 | Intracellular Ca ²⁺ Homeostasis in Trypomastigotes of <i>Trypanosoma cruzi</i> . <i>Journal of Eukaryotic Microbiology</i> , 1998, 45, 80-86. | 1.7 | 7 |
| 243 | Bone Density Testing: Science, the Media, and Patient Care. <i>Current Osteoporosis Reports</i> , 2014, 12, 227-229. | 3.6 | 7 |
| 244 | The potential use of antisclerostin therapy in chronic kidney disease – mineral and bone disorder. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 1. | 2.0 | 7 |
| 245 | Normocalcemic PHPT. , 2015, , 331-339. | | 7 |
| 246 | Drugs for the treatment of metabolic bone diseases. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1049-1051. | 2.4 | 7 |
| 247 | Tc99m-Sestamibi Uptake in Osteitis Fibrosa Cystica Simulating Metastatic Bone Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5138-5141. | 3.6 | 7 |
| 248 | Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 281-295. | 2.4 | 6 |
| 249 | Teriparatide: Variations on the theme of a 2-year therapeutic course. <i>IBMS BoneKEy</i> , 2010, 7, 84-87. | 0.0 | 6 |
| 250 | Bone Histomorphometry and Bone Quality in Primary Hyperparathyroidism. , 2015, , 429-445. | | 6 |
| 251 | Pre-operative localization of abnormal parathyroid tissue by 99mTc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency. <i>Endocrine</i> , 2018, 60, 36-45. | 2.3 | 6 |
| 252 | A Simple Formula to Estimate Parathyroid Weight on 4D-CT, Predict Pathologic Weight, and Diagnose Parathyroid Adenoma in Patients with Primary Hyperparathyroidism. <i>American Journal of Neuroradiology</i> , 2020, 41, 1690-1697. | 2.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Calcium Citrate Versus Calcium Carbonate in the Management of Chronic Hypoparathyroidism: A Randomized, Double-Blind, Crossover Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1251-1259. | 2.8 | 6 |
| 254 | Osteoporosis in Men: Pathophysiology and treatment. <i>Current Osteoporosis Reports</i> , 2007, 5, 22-28. | 3.6 | 5 |
| 255 | Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. <i>Journal of Drug Assessment</i> , 2012, 1, 11-19. | 2.2 | 5 |
| 256 | Osteoporosis. <i>Clinical Obstetrics and Gynecology</i> , 2013, 56, 730-738. | 1.1 | 5 |
| 257 | Parathyroid Hormone 1 α 84 Alters Circulating Vascular Endothelial Growth Factor Levels in Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2025-E2028. | 3.6 | 5 |
| 258 | Osteitis Fibrosa Cystica. <i>JBMR Plus</i> , 2020, 4, e10403. | 2.7 | 5 |
| 259 | Vitamin D status in Armenian women: a stratified cross-sectional cluster analysis. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 220-226. | 2.9 | 5 |
| 260 | Bone Quality as Measured by Trabecular Bone Score in Normocalcemic Primary Hyperparathyroidism. <i>Endocrine Practice</i> , 2021, 27, 992-997. | 2.1 | 5 |
| 261 | Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 331-336. | 0.6 | 5 |
| 262 | Anabolic therapy for osteoporosis. <i>International Journal of Fertility and Women's Medicine</i> , 2005, 50, 53-60. | 0.4 | 5 |
| 263 | Skeletal Imaging in Primary Hyperparathyroidism. , 2015, , 447-454. | | 4 |
| 264 | Primary Hyperparathyroidism: Epidemiology and Clinical Consequences. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002, 1, 25-34. | 0.8 | 3 |
| 265 | Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism. , 2015, , 489-497. | | 3 |
| 266 | Asymptomatic Primary Hyperparathyroidism. , 2015, , 317-330. | | 3 |
| 267 | Non-surgical management of primary hyperparathyroidism in the aging population. <i>Maturitas</i> , 2020, 136, 49-53. | 2.4 | 3 |
| 268 | Hungry bone syndrome following parathyroidectomy for primary hyperparathyroidism in a developed country in the Asia Pacific. A cohort study. <i>Osteoporosis and Sarcopenia</i> , 2022, 8, 11-16. | 1.9 | 3 |
| 269 | Does calcium intake influence the development of primary hyperparathyroidism?. <i>IBMS BoneKEy</i> , 2013, 10, . | 0.0 | 2 |
| 270 | Hypoglycemia Secondary to Sulfonylurea Ingestion in a Patient with End Stage Renal Disease: Results from a 72-Hour Fast. <i>Case Reports in Endocrinology</i> , 2015, 2015, 1-4. | 0.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Bone Turnover Markers in Primary Hyperparathyroidism. , 2015, , 423-428. | | 2 |
| 272 | Anabolic and Catabolic Pathways of Parathyroid Hormone on the Skeleton. , 2015, , 233-244. | | 2 |
| 273 | Primary hyperparathyroidism â€œ Hypercalcemic and normocalcemic variants. Current Opinion in Endocrine and Metabolic Research, 2018, 3, 42-50. | 1.4 | 2 |
| 274 | Association between fibroblast growth factor 23 and functional capacity among independent elderly individuals. Einstein (Sao Paulo, Brazil), 2021, 19, eAO5925. | 0.7 | 2 |
| 275 | Chapter 66. Primary Hyperparathyroidism. , 0, , 301-306. | | 2 |
| 276 | Reticulocyte Cytosol Activator Protein: Its Actions Upon the Beta Adrenergic Receptor and the N-Proteins of Adenylate Cyclase. Journal of Receptors and Signal Transduction, 1984, 4, 475-486. | 1.2 | 1 |
| 277 | Release of guanosine triphosphate binding protein Â subunits from mouse myocardial membranes: Basic properties and their alterations in acute murine Chagas disease. Cardiovascular Research, 1995, 29, 350-358. | 3.8 | 1 |
| 278 | Enhancement of parathyroid hormone-responsive renal cortical adenylate cyclase activity by a cytosol protein activator from rat reticulocytes. Journal of Bone and Mineral Research, 1986, 1, 41-50. | 2.8 | 1 |
| 279 | Lawrence G. Raisz November 13, 1925â€œAugust 25, 2010. Journal of Bone and Mineral Research, 2011, 26, 903-911. | 2.8 | 1 |
| 280 | Spontaneous Remission of Primary Hyperparathyroidism Related to an Autoimmune Disease: A Case Report. AACE Clinical Case Reports, 2015, 1, e255-e259. | 1.1 | 1 |
| 281 | Skeletal Manifestations of Hypoparathyroidism. , 2015, , 771-779. | | 1 |
| 282 | Brown tumors of primary hyperparathyroidism may be a source of extrarenal 1,25-dihydroxyvitamin D production. Endocrine, 2018, 60, 524-527. | 2.3 | 1 |
| 283 | Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases. Journal of Bone and Mineral Research, 2018, 33, 1900-1901. | 2.8 | 1 |
| 284 | Clinical and translational pharmacology of bisphosphonates. , 2020, , 1671-1687. | | 1 |
| 285 | Pharmacologic mechanisms of therapeutics. , 2020, , 1633-1642. | | 1 |
| 286 | Osteoanabolics Versus Antiresorptives: Which First?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 964-965. | 3.6 | 1 |
| 287 | Primary Hyperparathyroidism: Pathophysiology, Surgical Indications, and Preoperative Workup. , 2021, , 486-493.e2. | | 1 |
| 288 | Bone quality in hypoparathyroidism. Minerva Endocrinology, 2021, 46, 325-334. | 1.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Osteoporosis in Men. , 2014, , 323-333. | | 1 |
| 290 | Primary Hyperparathyroidism in Men. , 2010, , 465-478. | | 1 |
| 291 | FGF23 levels as a marker of physical performance and falls in community-dwelling very old individuals. Archives of Endocrinology and Metabolism, 2022, , . | 0.6 | 1 |
| 292 | Osteoporosis in men: Pathophysiology and treatment. Current Sexual Health Reports, 2008, 5, 83-89. | 0.8 | 0 |
| 293 | Effects of guanine nucleotides and parathyroid hormone on inositol 1,4,5-trisphosphate metabolism in canine renal cortical tubular cell membranes. Journal of Bone and Mineral Research, 1991, 6, 599-607. | 2.8 | 0 |
| 294 | New Approaches to Osteoporosis Therapeutics. , 2013, , 1963-1985. | | 0 |
| 295 | The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism and in Osteoporosis. , 2013, , 1249-1265. | | 0 |
| 296 | Drugs acting on the calcium receptor. , 2020, , 1657-1670. | | 0 |
| 297 | The skeletal actions of parathyroid hormone in primary hyperparathyroidism. , 2021, , 1159-1173. | | 0 |
| 298 | Hypocalcemic Crisis: Acute Postoperative and Long-Term Management of Hypocalcemia. , 2022, , 113-124. | | 0 |
| 299 | Replacement Therapy with PTH(1-84). , 2015, , 333-342. | | 0 |
| 300 | Primary Hyperparathyroidism; Current Management Guidelines. , 2017, , 331-341. | | 0 |
| 301 | Treatment with Parathyroid Hormone. , 2020, , 25-31. | | 0 |
| 302 | PTH and PTHrP Analogs: Treatment of Osteoporosis. Contemporary Endocrinology, 2020, , 349-362. | 0.1 | 0 |
| 303 | When should a gynecologist refer a patient for specialty care in osteoporosis?. International Journal of Fertility and Women's Medicine, 2003, 48, 132-6; discussion 137-8. | 0.4 | 0 |